Bartlett & CO. Wealth Management LLC Acquires 5,045 Shares of Abbott Laboratories $ABT

Bartlett & CO. Wealth Management LLC increased its holdings in Abbott Laboratories (NYSE:ABT) by 0.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,057,152 shares of the healthcare product maker’s stock after purchasing an additional 5,045 shares during the period. Abbott Laboratories makes up about 2.0% of Bartlett & CO. Wealth Management LLC’s investment portfolio, making the stock its 11th largest position. Bartlett & CO. Wealth Management LLC owned about 0.06% of Abbott Laboratories worth $143,783,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ABT. Loudon Investment Management LLC boosted its stake in shares of Abbott Laboratories by 15.0% during the second quarter. Loudon Investment Management LLC now owns 24,247 shares of the healthcare product maker’s stock valued at $3,298,000 after purchasing an additional 3,168 shares during the period. Impact Capital Partners LLC boosted its stake in shares of Abbott Laboratories by 1.6% during the second quarter. Impact Capital Partners LLC now owns 22,167 shares of the healthcare product maker’s stock valued at $3,015,000 after purchasing an additional 357 shares during the period. Childress Capital Advisors LLC boosted its stake in shares of Abbott Laboratories by 18.8% during the second quarter. Childress Capital Advisors LLC now owns 7,715 shares of the healthcare product maker’s stock valued at $1,049,000 after purchasing an additional 1,221 shares during the period. PFG Investments LLC boosted its stake in shares of Abbott Laboratories by 2.0% during the second quarter. PFG Investments LLC now owns 14,924 shares of the healthcare product maker’s stock valued at $2,030,000 after purchasing an additional 297 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. boosted its stake in shares of Abbott Laboratories by 2.9% during the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 28,058 shares of the healthcare product maker’s stock valued at $3,816,000 after purchasing an additional 800 shares during the period. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.6%

Shares of NYSE:ABT opened at $133.97 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm has a market capitalization of $233.17 billion, a PE ratio of 16.79, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. The firm’s 50-day moving average is $131.48 and its two-hundred day moving average is $131.22. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same period in the previous year, the company posted $1.14 earnings per share. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is 29.57%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ABT. Leerink Partners began coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They set a “market perform” rating and a $143.00 target price for the company. Wells Fargo & Company lowered their price objective on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research note on Friday, July 18th. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and upped their price objective for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada upped their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $145.22.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.